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Summary
Background.— Thrombus aspiration (TA) has been associated with high rates of thrombotic
material retrieval, which results in improved myocardial reperfusion. In addition, a recent
study has shown that systematic TA for treatment of ST-segment elevation myocardial infarction
(STEMI) related to de novo lesions improves patient outcomes.
Aims.— Evaluation of a single-centre experience of TA before percutaneous coronary interven-
tion (PCI) for stent thrombosis (ST) treatment.
Methods.— Between 2004 and 2006, we indexed 24 patients presenting with deﬁnite ST. All
patients underwent TA (Export Medtronic® 6F catheter) followed by PCI for ST treatment. Base-
line clinical and angiographic characteristics, and complications related to the TA device were
indexed.
Results.— The median time of ST occurrence was 7 days. All patients except one presented
with STEMI. Bare-metal and drug-eluting ST represented 70.8% and 29.2% of cases, respec-
tively. Mean stent length was 18.8± 5.6mm; mean stent diameter was 2.8± 0.4mm; mean
number of implanted stents was 1.58± 0.7. There was no failure to cross the catheter and no
TA device-related complications were reported. The numbers of patients with initial throm-
bolysis in myocardial infarction (TIMI) ﬂow grades 0, 1 and 2 were 15 (62.5%), 3 (12.5%) and 6
(25.0%), respectively. No patient had TIMI ﬂow grade 3 before TA. After TA, 16 (66.7%) patients
had TIMI ﬂow grade 3; ﬁnal procedural success was obtained in 23 (95.8%) patients. The 1-year
death rate was 12.5%.
Abbreviations: MACE, major adverse cardiovascular events; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation
myocardial infarction; TA, thrombus aspiration; TIMI, thrombolysis in myocardial infarction; ST, stent thrombosis.
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Conclusions.— In our experience, TA before PCI for ST treatment shows promising results, pro-
viding high rates of immediate reperfusion and ﬁnal angiographic success, and low death rates,
compared with the literature.
© 2009 Elsevier Masson SAS. All rights reserved.
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Résumé
Rationnel.— La technique de thrombo-aspiration (TA) permet d’aspirer du matériel thrombo-
tique au niveau de l’artère coronaire résultant ainsi en une amélioration de la reperfusion
myocardique. Par ailleurs, une étude récente a montré que l’utilisation systématique de cette
technique pour le traitement des infarctus avec sus-décalage du segment ST améliorait le
devenir des patients.
Objectifs.— Rapporter l’expérience monocentrique de l’utilisation de la technique de TA
avant angioplastie coronaire percutanée (ACP) dans le traitement des thromboses de
stent.
Méthodes.— Entre 2004 et 2006, nous avons répertorié 24 patients se présentant pour une
thrombose de stent documentée par angiographie. Tous ces patients ont eu une TA (cathéter
Medtronic Export® 6F) suivi d’une ACP pour le traitement de cette thrombose de stent. Les
caractéristiques cliniques et angiographiques ont été collectées ainsi que les complications
liées à l’utilisation du système de TA.
Résultats.— Le délai médian de survenue de la thrombose de stent était de sept jours. Tous
les patients sauf un se sont présentés avec un infarctus avec sus-décalage du segment ST.
La thrombose de stent était celle d’un stent nu dans 70,8 % des cas et d’un stent actif dans
29,2 % des cas. La longueur moyenne du stent était de 18,8± 5,6mm et le diamètre moyen de
2,8± 0,4mm. Le nombre moyen de stents implantés était de 1,58± 0,7. Il n’y a eu aucun échec
de franchissement du système de TA et aucune complication liée au système n’a été rapportée.
Avant TA, le nombre de patients avec un ﬂux TIMI 0, 1 et 2 était de 15 (62,5 %), 3 (12,5 %) et
6 (25 %), respectivement. Aucun patient n’avait un ﬂux TIMI 3 dans l’artère coupable. Après
TA, le nombre de patients en ﬂux TIMI 3 était de 16 (66,7 %) et un succès angiographique ﬁnal
a été obtenu chez 23 patients (95,8 %). Le taux de décès à un an après traitement était de
12,5 %.
Conclusion.— Dans notre expérience, l’utilisation d’un système de TA avant ACP pour le traite-
ment de la thrombose de stent semble prometteuse et a permis d’obtenir une restauration
immédiate d’un ﬂux TIMI 3 dans deux tiers des cas, des taux élevés de succès angiographique
ﬁnal et des taux de décès relativement bas en comparaison des données de la littéra-
. Tous droits réservés.
I
T
o
b
r
b
i
s
i
n
a
b
t
w
s
t
t
M
P
B
p
i
t
i
t
t
e
Pture.
© 2009 Elsevier Masson SAS
ntroduction
A in patients undergoing primary PCI for the treatment
f STEMI related to de novo lesions has been shown to
e feasible, safe and associated with improved myocardial
eperfusion and outcomes [1—3]. Indeed, in the throm-
us aspiration during percutaneous coronary intervention
n acute myocardial infarction (TAPAS) trial [4], TA before
tenting resulted in lower cardiac mortality and lower
ncidence of the composite endpoint of cardiac death or
on-fatal reinfarction at 1 year.
Stent thrombosis is a rare event but is usually associ-
ted with poor outcomes [5—10]. In addition, large thrombus
urden in this context is the rule rather than the excep-
ion and the beneﬁt of systematic TA in patients presenting
ith stent thrombosis is still poorly described. The present
tudy reports a single-centre experience of systematic TA for
he treatment of patients undergoing primary PCI for stent
hrombosis.
T
c
t
tethods
opulation and study design
etween August 2004 and December 2006, we indexed all
atients presenting with deﬁnite stent thrombosis (accord-
ng to the Academic Research Consortium deﬁnition) and
reated by primary PCI in our centre. All patients included
n this study underwent TA before PCI for stent thrombosis
reatment. Patients with previous thrombolysis and patients
reated by emergent coronary artery bypass surgery were
xcluded.
CI procedures for stent thrombosis treatmenthe device used for TA was the Export Medtronic® 6F
atheter. Then PCI, with or without coronary stent implan-
ation, was performed in accordance with the standard
echnique usually used in our catheterization laboratory
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Table 1 Baseline clinical and angiographic characteris-
tics (deﬁnite stent thrombosis, n = 24).
Variables
Baseline clinical characteristics
Age (years) 60.1± 12.3
Men 21 (87.5)
Hypertension 14 (58.3)
Tobacco smoking 11 (45.8)
Diabetes mellitus 10 (41.7)
Hypercholesterolaemia 14 (58.3)
Body mass index (kg/m2) 26.3± 3.9
Family history of
cardiovascular disease
6 (25)
Renal failure (clearance < 60
mL/kg)
3 (12.5)
Left ventricular ejection
fraction (%)
41± 13.5
Indication for initial percutaneous coronary intervention
STEMI 13 (54.2)
Non-STEMI 5 (20.8)
Stable angina 6 (25)
Clinical presentation at time of stent thrombosis
STEMI 23 (95.8)
Non-STEMI 1 (4.2)
Timing of stent thrombosis
Acute stent thrombosis 5 (20.8)
Sub-acute stent thrombosis 12 (50)
Late stent thrombosis 3 (12.5)
Very late stent thrombosis 4 (16.7)
Recent (<15 days) antiplatelet
therapy cessation
2 (8.3)
Initial angiographic characteristics
Multivessel disease 17 (70.8)
Target vessel
LAD 14 (58.3)
LCx 1 (4.2)
RCA 9 (37.5)
Reference vessel diameter
(mm)
2.8± 0.4
Type of stent
Bare-metal stent 17 (70.8)
Sirolimus stent 6 (25.0)
Paclitaxel stent 1 (4.2)
Number of stents 1.58± 0.7
Total stent length (mm) 18.8± 5.6
Maximal balloon diameter (mm) 2.8± 0.4
Balloon/artery ratio 1± 0.1
Angiographic success 24 (100)
Data are mean± standard deviation or number (%).Thrombus aspiration and stent thrombosis
[11]. All patients were pretreated with an intravenous
bolus of aspirin 500mg and an intravenous bolus of hep-
arin 50 IU/kg; they also received a 300—600mg loading dose
of clopidogrel. The use of glycoprotein IIb/IIIa inhibitors
and new stent implantation were at the discretion of the
physicians and were driven by clinical and angiographic
outcomes. Post-procedural treatment consisted of a combi-
nation of unfractionated heparin (12 IU/kg/h) or enoxaparin
(0.1mg/kg twice a day) in all patients for at least 72 h and
dual antiplatelet therapy with aspirin 75mg and clopidogrel
75mg once daily for at least 1 year.
Film review
All coronary angiograms were reviewed by two cardiologists
(A.S. and R.B.). The culprit lesion of stent thrombosis, initial
TIMI ﬂow grade, TIMI ﬂow grade just after TA and ﬁnal TIMI
ﬂow grade were analysed.
Follow-up
Clinical follow-up at 1 year was conducted by phone contact
or ofﬁce visits. In cases of new hospitalization, data were
obtained by a systematic review of the discharge letter. Dur-
ing the 1-year follow-up period, the composite endpoint,
which included death, recurrent myocardial infarction and
recurrent stent thrombosis, was indexed systematically.
Deﬁnitions
Final procedural success was deﬁned as normal TIMI ﬂow
grade 3 with a residual stenosis <30%. According to the
Academic Research Consortium deﬁnition, deﬁnite stent
thrombosis was deﬁned as an angiographic conﬁrmation of
stent thrombosis (the presence of a thrombus that originates
in the stent or in the segment 5mm proximal or distal to the
stent) associated with the presence of at least one of the
following criteria within a 48-h time window:
• acute onset of ischaemic symptoms at rest;
• new ischaemic electrocardiogram changes that suggest
acute ischaemia;
• typical rise and fall in cardiac biomarkers [12].
In patients where recurrent myocardial infarction was
suspected from clinical signs or symptoms after the initial
infarction, an immediate measurement of troponin and a
second sample 6 h later were obtained; recurrent myocar-
dial infarction was diagnosed if there was an increase in the
value in the second sample of ≥20% [13].
Statistical analysis
Continuous variables are expressed as mean± standard devi-
ation, except for the delays, which are expressed as median
[25th—75th percentile]. Categorical variables are expressed
as absolute number and percentage.
ResultsPopulation
During the study period, 31 patients presented with deﬁnite
stent thrombosis in our centre. Patients with prehospital
t
n
p
w
cSTEMI: ST-segment elevation myocardial infarction; LAD: left
anterior descending coronary artery; LCx: left circumﬂex
coronary artery; RCA: right coronary artery.hrombolysis (n = 5) and patients treated by emergent coro-
ary artery bypass surgery (n = 2) were excluded. Finally, 24
atients presented with deﬁnite stent thrombosis and under-
ent TA followed by PCI during the target period, and were
onsidered for the present study. The median time of stent
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thrombosis occurrence was 7 days [3—54]. Early stent throm-
bosis was most frequent and occurred in 70.8% of the cases
with a median time of 4.5 days.
Baseline characteristics of the patients are shown
in Table 1. The mean age of patients was 60.1± 12.3
years and 41.7% were diabetic. The mean stent length
was 18.8± 5.6mm and the mean stent diameter was
2.8± 0.4mm. Twenty-three (95.8%) patients presented with
STEMI; the last patient presented with non-STEMI. The left
anterior descending artery was the main location of the
stent thrombosis (58.3% of cases) followed by the right coro-
nary artery (37.5% of cases).
Altogether, 18 (75%) patients were on dual antiplatelet
therapy at the time of stent thrombosis; recent (<15 days)
cessations of aspirin (n = 1) and clopidogrel (n = 1) were
noted.
The stent thrombosis treatment is detailed in Table 2.
TA before PCI was performed in all patients. Glycoprotein
IIb/IIIa inhibitors were used in 58.3% of cases and a new
stent was implanted in 79.2% of cases.
Feasibility and safety
All TAs were performed by using the Export Medtronic® 6F
catheter. The technique was feasible in all cases. The num-
bers of patients with initial TIMI ﬂow grade 0, 1 and 2
were 15 (62.5%), 3 (12.5%) and 6 (25.0%), respectively. No
patient had TIMI ﬂow grade 3 before TA use. After TA the
number of patients with TIMI ﬂow grade 3 was 16 (66.7%).
Final procedural success was obtained in 23 (95.8%) patients
(Fig. 1).
There were no major complications related to the TA
technique itself: no visible dissection, no coronary artery
perforation, no catheter thrombosis occurrence and no
stroke.
Table 2 Stent thrombosis treatment (deﬁnite stent
thrombosis, n = 24).
Variables
Pre-hospital thrombolysis 0
Clopidogrel loading dose of 600mg 7 (29.2)
Clopidogrel loading dose of 300mg 17 (70.8)
Glycoprotein IIb/IIIa inhibitors 14 (58.3)
Thrombus aspiration 24 (100)
New stent implantation (mm) 19 (79.2)
Type of stent
Bare-metal stent 18 (75)
Sirolimus stent 0
Paclitaxel stent 1 (4.2)
Number of stents 1.3± 0.2
Total stent length (mm) 21.3± 2.3
Stent diameter (mm) 2.7± 0.3
Stent/artery ratio 1± 0.1
Post-dilatation after stent implantation 10 (41.7)
Maximal balloon pressure (bars) 14.2± 0.9
Angiographic success 23 (95.8)
Data are mean± standard deviation or number (%).
Figure 1. Thrombolysis in myocardial infarction (TIMI) ﬂow
grades before and after thrombus aspiration (TA) for stent throm-
bosis treatment, and ﬁnal rates of angiographic success.
Table 3 Major adverse cardiovascular events at 1 year
(deﬁnite stent thrombosis, n = 24).
Variables n (%)
In-hospital events
MACE 3 (12.5)
Death 1 (4.2)
Recurrent myocardial infarction 2 (8.3)
Recurrent stent thrombosis 2 (8.3)
Complication related to TA device 0
1-month events
MACE 5 (20.8)
Death 3 (12.5)
Recurrent myocardial infarction 4 (16.7)
Recurrent stent thrombosis 4 (16.7)
1-year events
MACE 5 (20.8)
Death 3 (12.5)
Recurrent myocardial infarction 4 (16.7)
Recurrent stent thrombosis 4 (16.7)
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ollow-up
he 1-year follow-up after the stent thrombosis episode is
etailed in Table 3. The rate of major adverse cardiovas-
ular events (MACE), including death, recurrent myocardial
nfarction and recurrent stent thrombosis, was 20.8% at 1
ear. There were three (12.5%) deaths and four (16.7%)
ecurrent stent thromboses leading to four (16.7%) recur-
ent myocardial infarctions. All events occurred within the
rst months after the ﬁrst stent thrombosis.
iscussione report here our single-centre experience of system-
tic TA use before PCI for stent thrombosis treatment. The
resent study shows promising results. Indeed, TA use facili-
ated high rates of immediate reperfusion, high rates of ﬁnal
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procedural success (up to 95.8%) and low rates of MACE at 1
year.
Stent thrombosis is a rare but severe complication of
PCI. According to the literature, the cumulative incidence
of deﬁnite stent thrombosis ranges between 1 and 1.5% at
1 year. Nevertheless, although not frequent, stent throm-
bosis remains a severe complication, responsible for high
rates of mortality (20—40%) and morbidity, including non-
fatal myocardial infarction in 70% of cases [5,7—10,14]. In
addition, after a ﬁrst episode, recurrent stent thrombosis
occurs in 15—30% of cases [15,16].
Consequently, the treatment of this complication is still
critical for cardiologists. In this context, Wenaweser et al.
have reported that the achievement of ﬁnal procedural suc-
cess, deﬁned as TIMI ﬂow grade 3 and residual stenosis <50%,
was the only predictor of death in a population of patients
presenting with deﬁnite stent thrombosis [16]. In addition,
TA use before PCI for treatment of STEMI related to a de
novo lesion has been shown to improve TIMI ﬂow grade
[2,3,17—19], resulting in an important outcome improve-
ment at 1 year [4]. Large thrombus burden has been reported
to be the rule rather than the exception in stent thrombosis.
Therefore, it may be of interest to use TA devices for stent
thrombosis treatment.
In our study, TA using the Export Medtronic® 6F catheter
was feasible in all patients and safe, with no related
complications. Further, TA use facilitated immediate reper-
fusion in two-thirds of cases and ﬁnal procedural success in
95.8% of cases, which are higher rates than those reported
in the literature. Indeed, ﬁnal procedural success after def-
inite stent thrombosis has been reported to be around 80%
in a large trial [20]. Our results are consistent with previous
reports. Indeed, small retrospective studies (including fewer
than 20 patients) have shown that systematic TA use for
stent thrombosis treatment improves the reperfusion suc-
cess rate up to 90% [21—23]. In addition, the rates of MACE
and death in the present study were only 20.8% and 12.5%
at 1 year, respectively, which are lower than rates reported
previously [5—10]. Finally, TA before balloon angioplasty or
stenting during primary PCI in STEMI has been shown to
reduce the occurrence of distal embolization by removing
macroscopic clots in the majority of cases in previous reports
[24].
Study limitations
The small sample size and retrospective design are the prin-
cipal limitations of the present study. In addition, systematic
anatomopathological analyses of the retrieved material are
lacking and may have been of interest. However, our results
are consistent with previous reports supporting TA use for
the treatment of stent thrombosis and STEMI related to de
novo lesions. Further studies are needed to enable deﬁnite
conclusions to be drawn on the beneﬁt of systematic TA use
in stent thrombosis treatment.Conclusions
In the present study, TA use for the treatment of deﬁnite
stent thrombosis showed promising results. In addition, the
[37
se of this device resulted in high rates of immediate and
nal myocardial reperfusion (up to 96%) and low rates of
ACE at 1 year, which are much better than results reported
n the literature in this context. Nevertheless, additional
tudies assessing the efﬁciency of systematic TA use for the
reatment of stent thrombosis are needed.
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